ArticleJournal of cancer research and clinical oncology2006
Dominant expression of 85-kDa form of cortactin in colorectal cancer.
Article in Journal of cancer research and clinical oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Targeted splicing therapy: new strategies for colorectal cancer.Frontiers in oncology · 2023Review
- Article
- Review
- Expression of Formin-like 2 and cortactin in gallbladder adenocarcinoma and their clinical significance.International journal of clinical and experimental pathology · 2020Article
- High expression of PTBP1 promote invasion of colorectal cancer by alternative splicing of cortactin.Oncotarget · 2017Article
- Chansu inhibits the expression of cortactin in colon cancer cell lines in vitro and in vivo.BMC complementary and alternative medicine · 2015Article
- A Golgi-based KDELR-dependent signalling pathway controls extracellular matrix degradation.Oncotarget · 2015Article
- Expression of cortactin and focal adhesion kinase in colorectal adenocarcinoma: correlation with clinicopathologic parameters and their prognostic implication.Korean journal of pathology · 2012Article
- Nucleating actin for invasion.Nature reviews. Cancer · 2011Review
- Further insights into cortactin conformational regulation.Bioarchitecture · 2011Article
- Article
- Expression of cortactin correlates with a poor prognosis in patients with stages II-III colorectal adenocarcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2010Article
- Regulation of the actin cytoskeleton in cancer cell migration and invasion.Biochimica et biophysica acta · 2007Article
- Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array.BMC genomics · 2006Article
- Invadopodia: specialized cell structures for cancer invasion.Clinical & experimental metastasis · 2006Review
- Prognosis of gastric adenocarcinoma associated with girdin, Akt, and cortactin.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCortactin is commonly expressed in several human cancers, which may alter their invasive or metastatic properties. Eighty five kilodalton form (p85) and 80-kDa form (p80) of cortactin are two separate bands in SDS-PAGE representing different conformational states. The objective of this study was to investigate cortactin expression in colorectal cancer (CRC). EXPERIMENTAL
designCortactin expression was studied in an eight paired laser capture microdissection (LCM) CRC tissues and matched non-cancerous epithelia by immunoblotting. The expression in 58 CRC and two cell lines, HCT8 and HCT116, was studied respectively by immunohistochemistry and confocal laser scanning immunofluorescence.
resultsDominant expression of p85 was identified in LCM-procured CRC tissues compared with equal intensity of p85 and p80 forms in non-cancerous tissues, while the amount of total cortactin was approximate. Immunohistochemistry analysis demonstrated that cortactin located in the cytoplasm of tumor cells and adjacent non-cancerous cells, and its expression was negatively correlated with TNM staging and lymphatic invasion status. However, the invasion fronts in 3 of 58 primary tumors and 28 of 39 available lymph node metastases were intensively stained. Further, immunofluorescence analysis showed that cortactin was distributed in cytoplasm and enriched in the front of the extending lamellipodia at adhering side of cultured cancer cells.
conclusionsOur results demonstrated the dominant expression of p85 form of cortactin in CRC for the first time. The enrichment of cortactin in the invasion front of some tumor cells and in the extending lamellipodia of cultured cancer cells suggests that cortactin may help cancer cell movement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.